Flavia Pease
Known title: EVP & CFOCIK: 0001924996
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
Transaction History
| PODD | ▼ Sell | Tax Withholding | 1,882 | $246K | 10/1/2026 | View on chart |
| PODD | ▲ Buy | Grant | 3,822 | $0 | 2/24/2026 | View on chart |
| PODD | ▲ Buy | Grant | 11,708 | $0 | 10/1/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 185 | $25K | 5/31/2025 | View on chart |
| CRL | ▲ Buy | Grant | 7,152 | $970K | 5/30/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 141 | $19K | 5/27/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 190 | $26K | 5/26/2025 | View on chart |
| PODD | ▲ Buy | Grant | 778 | $0 | 5/22/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 889 | $104K | 5/2/2025 | View on chart |
| CRL | ▲ Buy | Grant | 2,704 | $0 | 1/31/2025 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 914 | $151K | 1/31/2025 | View on chart |
| CRL | ▲ Buy | Grant | 2,159 | $0 | 5/31/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 144 | $31K | 5/27/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 212 | $46K | 5/26/2024 | View on chart |
| PODD | ▲ Buy | Grant | 1,380 | $0 | 5/22/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 893 | $208K | 5/2/2024 | View on chart |
| PODD | ▲ Buy | Grant | 1,471 | $0 | 1/18/2024 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 137 | $27K | 5/27/2023 | View on chart |
| CRL | ▲ Buy | Grant | 2,215 | $0 | 5/26/2023 | View on chart |
| CRL | ▲ Buy | Grant | 1,637 | $0 | 5/27/2022 | View on chart |
| CRL | ▲ Buy | Grant | 5,185 | $0 | 5/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4
Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.